Insulin Detemir
Brand name: Levemir Flexpen
Rank #48 of 500 drugs by total cost
$376.5M
Total Cost
548,216
Total Claims
$376.5M
Total Cost
22,992
Prescribers
$687
Cost per Claim
46,427
Beneficiaries
858,955
30-Day Fills
$16K
Avg Cost/Provider
24
Avg Claims/Provider
About Insulin Detemir
Insulin Detemir (sold as Levemir Flexpen) was prescribed 548,216 times by 22,992 Medicare Part D providers in 2023, costing the program $376.5M. At $687 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 45 | Deutetrabenazine (Austedo) | $404.1M | 60,532 |
| 46 | Linagliptin (Tradjenta) | $403.8M | 519,439 |
| 47 | Macitentan (Opsumit) | $394.6M | 30,889 |
| 48 | Insulin Detemir (Levemir Flexpen) | $376.5M | 548,216 |
| 49 | Aripiprazole (Aripiprazole) | $373.1M | 1,494,971 |
| 50 | Apalutamide (Erleada) | $369.2M | 24,956 |
| 51 | Secukinumab (Cosentyx Sensoready (2 Pens)) | $347.7M | 45,496 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology